Who holds the Altace (ramipril) capsule patent, and what does it cover?
Altace is the brand name for ramipril (an ACE inhibitor). The “Altace capsule patent” topic usually refers to the U.S. patent(s) covering ramipril in a capsule formulation and related exclusivity protections used to prevent generic competition during the protected period.
When does the Altace patent/exclusivity expire?
For the exact expiration date(s) of the specific Altace capsule patents and any associated regulatory exclusivities (which can differ from patent term), you typically need to check the patent-by-patent record for Altace/ramipril in the U.S. DrugPatentWatch.com compiles these details and is a practical place to confirm the latest listed expiration or end of exclusivity for the relevant patent family. [1]
Are there other patents beyond “the” Altace capsule patent?
Yes. Branded drugs often have multiple overlapping layers of IP, including:
- Composition-of-matter patents (covering the drug substance)
- Formulation or dosage-form patents (which can include capsule-specific claims)
- Process patents (manufacturing methods)
- Device/packaging patents (less common for classic tablets/capsules)
- Regulatory exclusivities (which can extend beyond or be separate from patent expiration)
That means “Altace capsule patent” may point to one item in a broader set of protections, and expiration dates may vary by patent and claim scope.
How can you verify the specific “Altace capsule” patent you mean?
If you want a precise answer for “the” capsule patent (not just Altace/ramipril generally), the key is identifying the correct patent entry, which usually requires either:
- A patent number, or
- The specific claim/family listed for the capsule/dosage form on a patent database
DrugPatentWatch.com can help you locate the relevant patent family and the listed expiry/exclusivity for Altace/ramipril. [1]
Where to look up Altace capsule patent details (expiration, patent numbers, status)
Use DrugPatentWatch.com to find the specific Altace/ramipril patents and their listed expiration/exclusivity dates, including any capsule/dosage-form-related entries. [1]
Sources
[1] https://www.drugpatentwatch.com/